Abstract 1251P
Background
Abnormal methylation of cell-free DNA (cfDNA) enables the diagnosis of lung cancer. In this study, we aimed to identify the best methylation marker for distinguishing lung cancer from healthy individuals, and then develop a deep learning algorithm using methylation and fragment size profiles (MFS) of cfDNA in that region.
Methods
We obtained 828 tissue samples from lung cancer patients, 74 adjacent normal tissue samples, and 656 samples of normal whole blood from the TCGA database and generated genome-wide tissue and plasma methylome data from healthy individuals and lung cancer patients using 215 Methylated DNA immunoprecipitation sequencing (MeDIP-Seq) and 24 Enzymatic Methyl-seq (EM-seq). A total of 366 DNA methylation markers were selected based on the methylation profiling of these datasets, and a targeted EM-seq panel was designed on these markers. The panel was used to produce 142 lung cancer samples (stage I: 26%, II: 11%, III: 42%, IV: 11%, unknown: 11%) and 56 healthy samples. MFS was trained on hyper- and hypo-methylated regions using convolutional neural networks. To confirm the limit of detection (LOD), sequencing was performed on diluted samples of healthy and lung cancer cfDNA with different ratios (tumor fractions of 0.1%, 0.5%, and 1%).
Results
We found that the performance was better in hypo-methylated regions than in hyper-methylated regions. The lung cancer detection performance in the test and external sets reached an accuracy of 81.5% (CI: 78.2% to 87.0%) and an AUC of 0.87 (CI: 0.83 to 0.94). At a specificity of 80%, the sensitivity for cancer detection was 77.5% (CI: 67.3% to 99.4%). The sensitivity for Lung Adenocarcinoma and Lung Squamous Cell Carcinoma at 80% specificity was 61.1% (CI: 42.7% to 94.4%) and 85.7% (CI: 71.4% to 100.0%), respectively. With serial dilution results, we detected down to 0.1% tumor fraction with a specificity of 80%.
Conclusions
This study developed and validated a methylation marker and deep learning model that can distinguish between lung cancer patients and healthy individuals using methylation and size information. This approach provides a sensitive and accurate diagnostic tool for lung cancer.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
GC Genome.
Funding
Ministry of Health and Welfare.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
1816P - Combination treatment with radium-223 (223Ra) and enzalutamide (enza) in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) in the REASSURE study
Presenter: Bertrand Tombal
Session: Poster session 14
1817P - A phase I/II efficacy and safety study of LAE001/prednisone and afuresertib in patients with metastatic castration-resistant prostate cancer (mCRPC) following 1-3 lines of standard of care
Presenter: Elan Diamond
Session: Poster session 14
1818P - Final results from a randomized phase II study of cabazitaxel (CBZ) versus an androgen receptor targeted agent (ARTA) in patients with poor-prognosis castration-resistant prostate cancer (mCRPC)
Presenter: Kim van der Zande
Session: Poster session 14
1819P - PSMA-BAT: Prospective biomarker trial of patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) undergoing bipolar androgen therapy (BAT)
Presenter: Aline Lara Gongora
Session: Poster session 14